Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
May 28, 2002
SAN DIEGO, May 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) ("Arena") today announced the signing of a research and license agreement with Ferring Pharmaceuticals, Inc. (Ferring), a unit of privately-held Ferring Holding S.A., a biopharmaceutical company with operations in 35 countries and products di...
Apr 24, 2002
SAN DIEGO, Apr 24, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $4.2 million for the quarter ended March 31, 2002, versus $5.4 million in revenues for the quarter ended March 31, 2001. Revenues in the first quarter of 2002 and 2001 were attributable to collaborations, which incl...
Apr 4, 2002
SAN DIEGO, Apr 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet first quarter conference call on Wednesday, April 24, 2002 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph ...
Jan 17, 2002
SAN DIEGO, Jan. 17 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported record revenues of $5.9 million for the quarter ended December 31, 2001, a 44% increase over fourth quarter 2000 revenues, and $18.1 million for the full year ended December 31, 2001, a 135% increase over the full year ended December 31, 2000....
Jan 3, 2002
SAN DIEGO, Jan 3, 2002 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet fourth quarter conference call on Thursday, January 17, 2002 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, ...
Nov 7, 2001
SAN DIEGO, Nov. 7 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has completed its initial analysis of human G protein-coupled receptor (GPCR) gene expression in 80 normal human tissues. Utilizing a proprietary, custom-designed, oligonucleotide "GPCR chip," Arena has identified relative expression l...
Oct 18, 2001
SAN DIEGO, Oct. 18 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.5 million for the quarter ended September 30, 2001, a 50% increase over third quarter 2000 revenues, and $12.2 million for the nine months ended September 30, 2001, a 238% increase over the nine months ended September 30, 2000. ...
Oct 2, 2001
SAN DIEGO, Oct 2, 2001 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet third quarter conference call on Thursday, October 18, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, c...
Aug 31, 2001
SAN DIEGO, Aug 31, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet conference call on Wednesday September 5, 2001 at 4:15 p.m. Eastern Time (1:15 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial officer...
Aug 20, 2001
SAN DIEGO, Aug 20, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA); ("Arena") today announced the signing of a license agreement with TaiGen Biotechnology Co., Ltd. ("TaiGen"), a privately-held biopharmaceutical organization located in Taipei, Taiwan. Under the terms of the agreement, TaiGen has the right to select validated scr...
Jul 23, 2001
SAN DIEGO, Jul 23, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported revenues of $3.3 million for the quarter ended June 30, 2001, a 158% increase over second quarter 2000 revenues, and $8.7 million for the six months ended June 30, 2001, a 576% increase over the six months ended June 30, 2000. Increased revenues in...
Jul 9, 2001
SAN DIEGO, July 9 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has entered into an agreement with the ICI group to apply Arena's proprietary CART technology to olfactory and gustatory G protein-coupled receptors (GPCRs). The initial stage of the research will last at least six months and Arena int...
Jul 5, 2001
SAN DIEGO, Jul 5, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it will host both a telephone and internet second quarter conference call on Monday, July 23, 2001 at 4:30 p.m. Eastern Time (1:30 p.m. San Diego Time). Jack Lief, president and chief executive officer, and Joseph Mooney, chief financial...
Jul 2, 2001
SAN DIEGO, Jul 2, 2001 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the underwriting group managed by Thomas Weisel Partners LLC, Dain Rauscher Wessels, ABN AMRO Rothschild LLC and Lazard Freres & Co. LLC., have exercised their over-allotment option in connection with Arena's June 21, 2001 secondary offeri...
Jun 22, 2001
SAN DIEGO, June 22 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that its follow-on offering of 5,000,000 shares of its common stock was priced on June 21, 2001 at $27.50 per share. Of the 5,000,000 shares, Arena offered 4,000,000 shares and two selling stockholders offered a total 1,000,000 shares. Arena...
= add release to Briefcase